Patents by Inventor Sylvain Doré

Sylvain Doré has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATING TO OXIDATIVE STRESS
    Publication number: 20150080462
    Abstract: The present invention features methods for treating or preventing conditions, diseases, or disorders related to oxidative stress. In one embodiment, the method increases Nrf2 biological activity or expression. In particular, the invention provides for the treatment or prevention of diseases relating to oxidative stress including emphysema, sepsis, septic shock, ischemic injury, cerebral ischemia and neurodegenerative disorders, meningitis, encephalitis, hemorrhage, cerebral ischemia, heart ischemia, cognitive deficits and neurodegenerative disorders.
    Type: Application
    Filed: August 4, 2014
    Publication date: March 19, 2015
    Inventors: Shyam Biswal, Sylvain Dore, Rajesh Kumar Thimmulappa, Tirumalai Rangasamy, Yoshihito Sakata, Zahoor Ahmad Shah, Hean Zhuang, Anju Singh
  • TREATMENT AND PREVENTION OF ISCHEMIC BRAIN INJURY
    Publication number: 20100251394
    Abstract: The invention provides methods of identifying agents for treating and preventing ischemic brain injury.
    Type: Application
    Filed: September 22, 2008
    Publication date: September 30, 2010
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventor: Sylvain Doré
  • TREATMENT AND PREVENTION OF ISCHEMIC BRAIN INJURY
    Publication number: 20100229250
    Abstract: The invention provides methods of identifying agents for treating and preventing ischemic brain injury.
    Type: Application
    Filed: September 22, 2008
    Publication date: September 9, 2010
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventor: Sylvain Dore
  • ANTAGONISTS OF PGE2 EP3 RECEPTORS
    Publication number: 20100074896
    Abstract: PGE2 EP3 receptors affect injury size following cerebral ischemia and induced excitotoxicity. Treatment with selective EP3 antagonists decreases infarct size. In addition, such antagonists can reduce lesions caused by N-methyl-D-aspartic acid-induced acute excitotoxicity. Similarly, genetic deletion of EP3 provides protection against N-methyl-D-aspartic acid-induced toxicity. PGE2, by stimulating EP3 receptors, can contribute to the toxicity associated with cyclooxygenase and that antagonizing this receptor can be used therapeutically to protect against stroke- and excitotoxicity-induced brain damage.
    Type: Application
    Filed: November 30, 2007
    Publication date: March 25, 2010
    Applicant: The Johns Hopkins University
    Inventors: Sylvain Dore, Abdullah Ahmad
  • Method for the Prevention and/or Treatment of Neurodegenerative Diseases Characterized by Administering and Ep1 Receptor Antagonist
    Publication number: 20080312326
    Abstract: The present invention relates to the use of EP1 receptor antagonists for the treatment of neurodegenerative diseases, for example, Alzheimer's disease, Parkinson's disease, Parkinson syndrome, dementia, amyotrophic lateral sclerosis, progressive supranuclear palsy, Huntington's disease, spinocerebellar ataxia, etc.
    Type: Application
    Filed: May 25, 2006
    Publication date: December 18, 2008
    Applicant: THE JOHN HOPKINS UNIVERSITY
    Inventor: Sylvain Dore